BioLife Solutions (NASDAQ: BLFS) shares Repligen merger video with staff
Rhea-AI Filing Summary
BioLife Solutions, Inc. describes progress on its pending merger into Repligen Corporation. Under a July 21, 2026 Agreement and Plan of Merger, BioLife will first merge with a Repligen subsidiary and become a wholly owned Repligen subsidiary, followed by a second merger into another Repligen subsidiary.
The company reports that on August 3, 2026 its management distributed an internal email linking to a video from Repligen’s CEO introducing Repligen and discussing anticipated benefits of combining, including expectations for growth in the cell therapy market. The email and video transcript are furnished as exhibits under Regulation FD.
Management statements emphasize that the transaction remains subject to regulatory clearances and BioLife stockholder approval and is expected to close later this year in the fourth quarter. Extensive forward-looking language outlines potential benefits such as anticipated synergies and accretion, as well as risks related to approvals, integration, market conditions, potential legal proceedings and dilution at Repligen. Investors are directed to an upcoming Form S-4 registration statement and joint proxy statement/prospectus for detailed terms.
Positive
- BioLife describes a pending merger with Repligen that both companies’ managements believe is financially compelling and accretive in the near term, with anticipated synergies and growth opportunities in the cell therapy tools market.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Merger Agreement date: July 21, 2026
Repligen founding year: 1981
Repligen headcount: around 2,000 people
+2 more
5 metrics
Merger Agreement date
July 21, 2026
Date BioLife entered the Agreement and Plan of Merger with Repligen and subsidiaries
Repligen founding year
1981
Year Repligen was founded by two scientists
Repligen headcount
around 2,000 people
Approximate size of Repligen’s global team described by its CEO
Repligen Form 10-K period
year ended December 31, 2025
Reporting period for Repligen’s referenced Annual Report on Form 10-K
Latest Form 10-Q period
three months ended March 31, 2026
Quarterly period referenced for both Repligen’s and BioLife’s Form 10-Qs
Key Terms
Agreement and Plan of Merger, registration statement on Form S-4, proxy statement/prospectus, forward-looking statements, +1 more
5 terms
Agreement and Plan of Merger regulatory
"entered into an Agreement and Plan of Merger by and among, BioLife, Repligen Corporation"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
registration statement on Form S-4 regulatory
"Repligen will file with the SEC a registration statement on Form S-4"
A registration statement on Form S-4 is a formal filing with the U.S. Securities and Exchange Commission used when a company issues shares or other securities as part of a merger, acquisition, exchange offer or similar corporate deal. It bundles the transaction terms, financial statements, risk factors and shareholder vote materials so investors can assess the deal; think of it as a detailed prospectus or buyer’s packet that explains what you would own and how the deal could change your stake.
proxy statement/prospectus regulatory
"which will contain a proxy statement of BioLife and a prospectus of Repligen"
A proxy statement or prospectus is a document that companies send to shareholders to provide important information about upcoming decisions or investments, such as voting on company issues or offering new shares to the public. It helps investors understand the details and risks involved, enabling them to make informed choices about their ownership or involvement with the company.
forward-looking statements regulatory
"Statements included in this communication, which are not historical in nature ... are forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
cell therapy market financial
"Together will be even stronger in the fast growing cell therapy market"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What merger involving BioLife Solutions (BLFS) is described in this report?
BioLife Solutions outlines a pending two-step merger with Repligen Corporation. BioLife will merge into a Repligen subsidiary, then into a second subsidiary, ultimately becoming a direct wholly owned subsidiary of Repligen if the transaction is completed.
When is the BioLife Solutions (BLFS) and Repligen merger expected to close?
The companies state that the merger is expected to close in the fourth quarter of the current year. This timing depends on receiving required regulatory approvals and BioLife stockholder approval, as well as satisfaction of other merger agreement conditions.
What employee communications did BioLife Solutions (BLFS) furnish about the merger?
BioLife reports that management circulated an email on August 3, 2026 linking to an internal video from Repligen’s CEO. The video transcript and the circulating email are furnished as Exhibits 99.1 and 99.2 under Regulation FD.
What approvals are required for the BioLife Solutions (BLFS) merger with Repligen?
Completion of the merger requires regulatory approvals and BioLife stockholder approval, along with satisfaction or waiver of other specified conditions in the merger agreement. Failure to obtain these approvals could prevent or delay the transaction.
What forward-looking benefits and risks are discussed for the BioLife Solutions (BLFS) merger?
Management discusses expected synergies, revenue growth and near-term accretion, plus a stronger position in cell therapy tools. Risks include possible failure to obtain approvals, integration challenges, market conditions, legal proceedings and potential dilution from Repligen shares issued in the merger.
Which SEC filings should BioLife Solutions (BLFS) investors review regarding the merger?
Investors are directed to an upcoming registration statement on Form S-4 containing a joint proxy statement/prospectus, as well as existing Form 10-K and Form 10-Q reports of both companies available through the SEC and company websites.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (425 ) 402-1400
| N/A | ||
| (Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of exchange on which registered | ||||||
The | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 7.01 Regulation FD Disclosure.
As previously disclosed, on July 21, 2026, BioLife Solutions, Inc., a Delaware corporation (“BioLife” or the “Company”), entered into an Agreement and Plan of Merger by and among, BioLife, Repligen Corporation, a Delaware corporation (“Repligen”), Bravo Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Repligen (“Merger Sub 1), and Bravo Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Repligen (“Merger Sub 2”).
Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub 1 will be merged with and into BioLife (the “First Merger”), with BioLife surviving the First Merger as a direct, wholly owned subsidiary of Repligen (the “Surviving Company”), and immediately following the First Merger, the Surviving Company will be merged with and into Merger Sub 2 (the “Second Merger,” and, together with the First Merger, the “Mergers”), with Merger Sub 2 surviving the Second Merger as a direct, wholly owned subsidiary of Repligen.
On August 3, 2026, BioLife management circulated an email to BioLife’s employees containing a video recorded by Repligen management that provides additional information regarding Repligen and the Mergers (the “Employee Video”). A transcript of the Employee Video is furnished as Exhibit 99.1 to this Current Report on Form 8-K and a copy of the circulating email is furnished as Exhibit 99.2 to this Form 8-K, each of which is incorporated herein by reference.
The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Employee Video Transcript, dated August 3, 2026 | |||||||
| 99.2 | Circulating Email, dated August 3, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
Cautionary Statement Regarding Forward-Looking Statements
Statements included in this communication, which are not historical in nature or do not relate to current facts, are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provisions of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements are based on, among other things, Repligen management’s and BioLife management’s beliefs, assumptions, current expectations, estimates and projections about the economy and Repligen and BioLife, as applicable, and the industries in which Repligen and BioLife operate. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements.
Forward-looking statements include statements regarding, among other things, the expected benefits of the Mergers and Repligen’s ability to recognize the benefits of the Mergers; the anticipated timing of the closing of the Mergers; the anticipated financial impact of the Mergers on Repligen and the belief that this is a financially compelling transaction and accretive in the near-term; expectations for Repligen’s performance following the Mergers, including future financial and operating results; beliefs that the Mergers will accelerate profitable growth; beliefs and expectations about the cell therapy industry, including its growth, and BioLife’s position as a highly-differentiated cell processing tool leader; anticipated synergies; beliefs about the drivers for future growth following the Mergers, including with respect to the pipeline and regulatory matters; the expected impact on customers and revenue opportunities; BioLife’s second quarter results; Repligen’s second quarter results, including revenue growth and expectations for strong margin expansion; and Repligen’s plans, objectives, expectations, intentions, growth strategies and other statements that are not historical facts. Repligen and
BioLife caution readers that forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities: the occurrence of any event, change or other circumstances that could give rise to the right of one or both of the parties to terminate the Merger Agreement; the outcome of any legal proceedings that may be instituted against Repligen or BioLife; the failure to obtain necessary regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect Repligen following the Mergers, or the expected benefits of the Mergers); the failure to obtain BioLife Stockholder Approval or to satisfy any of the other conditions to the Mergers on a timely basis or at all; the possibility that the anticipated benefits of the Mergers, including anticipated synergies, financial impact and revenue growth, are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Repligen and BioLife do business; the risk that the parties have overestimated the size or trajectory of the cell therapy market and BioLife’s market position; the potential for increased regulatory scrutiny and the impact on the clinical pipeline, global approvals and expanded indications; the possibility that the Mergers may be more expensive to complete than anticipated; diversion of BioLife and Repligen management’s attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Mergers; risks relating to the potential dilutive effect of shares of Repligen common stock to be issued in the Mergers and other factors that may affect future results of Repligen. Additional factors that could cause results to differ materially from those described above can be found in Repligen’s Annual Report on Form 10-K for the year ended December 31, 2025, Repligen’s Quarterly Report on Form 10-Q for the three months ended March 31, 2026, BioLife’s Annual Report on Form 10-K for the year ended December 31, 2025, as amended by BioLife’s Annual Report on Form 10-K/A filed with the U.S. Securities and Exchange Commission (the “SEC”), on April 28, 2026 (collectively, the “BioLife 2025 Form 10-K”), BioLife’s Quarterly Report on Form 10-Q for the three months ended March 31, 2026, in each issuer’s respective Current Reports on Form 8-K and in other documents Repligen and BioLife file with the SEC, which are available on the SEC’s website at www.sec.gov. Repligen and BioLife caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Repligen and BioLife each disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Important Additional Information and Where to Find It
In connection with the Mergers, Repligen will file with the SEC a registration statement on Form S-4 (the “registration statement”), which will contain a proxy statement of BioLife and a prospectus of Repligen (the “proxy statement/prospectus”), and each of Repligen and BioLife may file with the SEC other relevant documents regarding the Mergers. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS CAREFULLY AND IN THEIR ENTIRETY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BY REPLIGEN AND BIOLIFE, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REPLIGEN, BIOLIFE AND THE MERGERS. When final, a definitive copy of the proxy statement/prospectus will be mailed to BioLife stockholders. Investors and security holders will be able to obtain the registration statement and the proxy statement/prospectus, as well as other filings containing information about Repligen and BioLife, free of charge from Repligen or BioLife or from the SEC’s website when they are filed. The documents filed by Repligen with the SEC may be obtained free of charge at Repligen’s website, at www.repligen.com, or by requesting them by mail at Repligen Corporation, 41 Seyon Street Building 1, Suite 100 Waltham, Massachusetts 02453, Attention: Corporate Secretary. The documents filed by BioLife with the SEC may be obtained free of charge at BioLife’s website, at www.biolifesolutions.com, or by requesting them by mail at BioLife Solutions, Inc., 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021, Attention: Corporate Secretary. The information included on Repligen’s and BioLife’s websites is not incorporated by reference into this communication.
Participants in the Solicitation
Repligen and BioLife and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of BioLife in respect of the Mergers. Information about Repligen’s directors and executive officers is available in Repligen’s proxy statement, dated April 2, 2026, for its 2026 Annual Meeting of Stockholders, and other documents filed by Repligen with the SEC. Information about BioLife’s directors and executive officers is available in the BioLife 2025 Form 10-K, in the Form 3 and Form 4 statements of beneficial ownership and statements of changes in beneficial ownership filed with the SEC by BioLife’s directors and executive
officers, and other documents filed by BioLife with the SEC. Other information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the Mergers when they become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Repligen or BioLife as indicated above.
No Offer or Solicitation
This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BioLife Solutions, Inc. | ||||||||
Date: August 3, 2026 | By: | /s/ Troy Wichterman | ||||||
| Name: Troy Wichterman | ||||||||
| Title: Chief Financial Officer | ||||||||
Hello to everyone at Bio Life Solutions. I'm Olivier Loeillot, President and CEO of Repligen. I'm very happy to have this opportunity to speak with you directly today. This is an exciting moment for all of us, and I wanted you to hear from me personally. Let me start by saying how much we admire what you've built with Rod and Troy, and the entire management team for nearly four decades now. You've become the trusted name in cell processing tools and biopreservation media. Your CryoStor platform supports commercially approved cell therapies and the majority of US cell based therapy trials. And honestly, that's remarkable and it's a reputation you earned. While you're still getting to know us, let me share a little bit more about who we are here at Repligen. We were founded in 1981 by two scientists with a bold science driven mission. Today we are headquartered in Waltham, Massachusetts, which is where I am today by the way. And we're a global team of around 2,000 people across North America, Europe and Asia. I have spent 30 years in this industry and I can tell you what makes Repligen special is our focus. We are a bioprocessing company. We build the tools and technologies that help our customers make biologic drugs faster, with higher yield and with better quality. We don't make the therapies ourselves. We make it easier for our partners to bring those life changing therapies to patients. And that mission is very simple. It's to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. So why do you think you'll be excited to be part of our team? Let me give you a few reasons. First, we are a really fast growing company. We've grown very much through innovation, but also a lot by welcoming great companies just like yours to our team. And that means real momentum and real opportunity for all of you in the company. Second, we are a company that is focused on innovation. I mean we are really the first to market again and again in the areas that really matter to most of our customers and we're working on some genuinely breakthrough technologies right now. And third and this is the one closest to my heart, it's really our people and our culture. We live by what we call the “R team.” We team up and work as one Repligen. We really engage authentically and welcome debate. We achieve with excellence and we move things forward with urgency. Those are not words on the wall. I mean, that's really how we show up for each other every single day. And that's exactly why bringing our two companies together feels so natural. We share the same DNA, passion for innovation, a customer first mindset and a real commitment to advancing the science that improves human health. Together will be even stronger in the fast growing cell therapy market and will do work that truly matters for patients around the world. Now I want to be very clear and very honest with you about where things stand today. The announcement shared on July 22nd was a very important first step, but it is just a first step. The transaction still needs regulatory and shareholder approvals and we expect to close later this year in the fourth quarter. Until then, Repligen and BioLife will continue to operate as two separate independent companies. So for
now, I ask it simple. Just keep doing the great work you are already doing and just keep taking care of your customers the way you always have. There is meaningful work ahead as we plan for the future together, and I promise we'll keep you informed every step of the way. I mean it when I say I can't wait for the day we can officially call you Repligen colleagues. Until then, thank you. Thank you for the incredible foundation you've built and for everything you're going to bring to this next chapter. Here's to a bright future for all of us. Take care everyone. I'll see you soon. Thanks.
Hello BioLife Team, The link below takes you to a video sent to us by Olivier Loeillot, Repligen’s President and CEO (you may need to right click on the link and select “open hyperlink”). VD_BioLife_Olivier_30JUL2026 2.mp4 Please take a few minutes to watch it and I think you will note Olivier’s genuine enthusiasm for our pending transaction and the positive impact on both companies it is expected to have. As always, should you have any questions, please feel free to reach out to me directly. Best regards, Rod Roderick de Greef Chairman and CEO rdegreef@BioLifeSolutions.com